カテゴリ： GlobalData, アイルランド, 企業調査

Prothena Corp Plc (PRTA)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Prothena Corp Plc (PRTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013515
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：72
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アイルランド
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Prothena Corp Plc (Prothena) is a biotechnology company that discovers, develops and markets novel antibodies that are indicated for the treatment of diseases associated with amyloid or cell adhesion. The company develops monoclonal antibodies directed specifically at disease-causing proteins. Its pipeline products comprise PRX002, indicated for the treatment of Parkinson’s disease; NEOD001, indicated for the treatment of primary systemic amyloidosis; PRX003, indicated for the treatment of psoriasis and other inflammatory diseases. The company offers research and development programs to other pharmaceutical and biotechnology companies. Prothena is headquartered in Dublin, Ireland.

Prothena Corp Plc (PRTA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Prothena Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Prothena Corp Plc, Medical Devices Deals, 2011 to YTD 2017 10
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
MJFF Enters into Agreement with Prothena 12
Licensing Agreements 13
Roche Enters into Licensing Agreement with Prothena 13
Roche Enters Into Licensing Agreement With Prothera 14
Equity Offering 16
Prothena Raises USD155.3 Million in Public Offering of Shares 16
Prothena Raises USD137 Million in Public Offering of Shares 18
Prothena Raises USD122 Million in Public Offering of Shares 20
Prothena Completes Exercise of Underwriter’s Over Allotment Option for Public Offering of Shares for USD123 Million 22
Prothena Completes Public Offering Of Shares For US$92 Million 24
Prothena Corp Plc – Key Competitors 26
Prothena Corp Plc – Key Employees 27
Prothena Corp Plc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 07, 2017: Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update 29
Aug 08, 2017: Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update 31
May 09, 2017: Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update 33
Feb 14, 2017: Prothena Reports Fourth Quarter and Full Year 2016 Financial Results, and Provides Financial Guidance and R&D Update 35
Nov 01, 2016: Prothena Reports Third Quarter 2016 Financial Results and Provides R&D Update 37
Aug 02, 2016: Prothena Reports Second Quarter 2016 Financial Results; Provides R&D Update 39
May 03, 2016: Prothena Reports First Quarter 2016 Financial Results and Provides R&D Update 41
Feb 18, 2016: Prothena Reports Fourth Quarter and Full Year 2015 Financial Results; Provides Financial Guidance and R&D Update 43
Corporate Communications 45
Jun 12, 2017: Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer 45
May 16, 2017: Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer 46
Oct 03, 2016: Prothena Announces Appointment of Dr. Gene G. Kinney as President, Chief Executive Officer and Director 47
Sep 06, 2016: Prothena Announces Appointment of Gene G. Kinney as Chief Operating Officer 48
Feb 24, 2016: Prothena Announces Appointment of Chief Commercial Officer 49
Product News 50
11/03/2016: Data for Prothena NEOD001 to be Presented at the 58th Annual American Society of Hematology Meeting 50
07/05/2016: Prothena Presents New Data from Phase 1/2 Study of NEOD001 Demonstrating Improvements in Three Organ Systems in Previously-Treated Patients with AL Amyloidosis 52
06/21/2016: Prothena to Present at 15th International Symposium on Amyloidosis Showcasing Broad Commitment to Advancing New Therapies for Systemic Amyloidoses 55
05/23/2016: Prothena to Present Wide Range of Studies on Amyloidosis, Including New Clinical Data on NEOD001, at International Symposium on Amyloidosis 57
02/09/2016: Data From Prothena Ongoing Phase 1/2 Clinical Trial of NEOD001 in AL Amyloidosis Published in the Journal of Clinical Oncology 58
Clinical Trials 60
Sep 18, 2017: Prothena Presents New Research Supporting Clinical Relevance of Cardiac Biomarker NT-proBNP in AL Amyloidosis 60
Aug 15, 2017: Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting 62
Apr 02, 2017: Clinical Results Presented from Prothena’s Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson’s Disease 63
Mar 09, 2017: Results for Prothena’s Phase 1b Multiple Ascending Dose Study of PRX002/RG7935 in Patients with Parkinson’s Disease to be Presented at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases 65
Dec 13, 2016: First-In-Human Assessment of PRX002, Prothenas Anti-Alpha Synuclein Antibody for Parkinsons Disease, Published in Movement Disorders Journal 67
Nov 09, 2016: Prothena Reports Results from Phase 1b Study of PRX002 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson’s Disease 68
Mar 16, 2016: Data from Prothena’s Preclinical Program on Conformation-Specific Antibodies Against Misfolded Transthyretin Published in Amyloid 70
Mar 16, 2016: Data from Prothena’s Preclinical Program on Conformation-Specific Antibodies Against Misfolded Transthyretin Published in Amyloid 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72

List of Tables
Prothena Corp Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Prothena Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Prothena Corp Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Prothena Corp Plc, Medical Devices Deals, 2011 to YTD 2017 10
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
MJFF Enters into Agreement with Prothena 12
Roche Enters into Licensing Agreement with Prothena 13
Roche Enters Into Licensing Agreement With Prothera 14
Prothena Raises USD155.3 Million in Public Offering of Shares 16
Prothena Raises USD137 Million in Public Offering of Shares 18
Prothena Raises USD122 Million in Public Offering of Shares 20
Prothena Completes Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD123 Million 22
Prothena Completes Public Offering Of Shares For US$92 Million 24
Prothena Corp Plc, Key Competitors 26
Prothena Corp Plc, Key Employees 27
Prothena Corp Plc, Subsidiaries 28

★海外企業調査レポート[Prothena Corp Plc (PRTA)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • FBD Holdings Plc (EG7)：企業の財務・戦略的SWOT分析
    FBD Holdings Plc (EG7) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Orange and Rockland Utilities, Inc.：企業の戦略的SWOT分析
    Orange and Rockland Utilities, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Pudumjee Paper Products Limited：企業の戦略・SWOT・財務分析
    Pudumjee Paper Products Limited - Strategy, SWOT and Corporate Finance Report Summary Pudumjee Paper Products Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Management Consulting Group Plc (MMC)：企業の財務・戦略的SWOT分析
    Summary Management Consulting Group plc (MCG), formerly Proudfoot Consulting Plc, is a professional services consultancy firm. The company through its subsidiaries designs, implements and accelerates operational transformation for the long-term benefit of a business. It provides consultancy and mana …
  • Pon Holdings B.V.：企業のM&A・事業提携・投資動向
    Pon Holdings B.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pon Holdings B.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Bang & Olufsen AS：企業の戦略・SWOT・財務情報
    Bang & Olufsen AS - Strategy, SWOT and Corporate Finance Report Summary Bang & Olufsen AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Maverick Natural Resources LLC：企業の戦略的SWOT分析
    Maverick Natural Resources LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Zynerba Pharmaceuticals Inc (ZYNE)-製薬・医療分野：企業M&A・提携分析
    Summary Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz, Inc., focuses on the development of next-generation synthetic cannabinoid therapeutics. The company’s pipeline product candidates include ZYN002 and ZYN001. Zynerba’s ZYN002 is a synthetic CBD, a non-psychoactive canna …
  • Promore Pharma AB：製薬・医療：M&Aディール及び事業提携情報
    Summary Promore Pharma AB (Promore), formerly Pergamum AB is a biopharmaceutical company that develops peptide-based product candidates for local and topical treatment of infections and wounds. The company’s pipeline products include LL-37 and PXL01 therapeutic peptides. Its PXL01 is used for the pr …
  • 3M Co (MMM)：電力：M&Aディール及び事業提携情報
    Summary 3M Company (3M) is a diversified technology company that specializes in the development, manufacture and marketing of a wide range of innovative products. The company develops technology platforms, including adhesives, abrasives, light management, microreplication, non woven materials, nanot …
  • ViraTherapeutics GmbH：製薬・医療：M&Aディール及び事業提携情報
    Summary ViraTherapeutics GmbH (ViraTherapeutics) is a biotechnology company that develops high potential anti-cancer therapeutics based on cancer-destroying oncolytic viruses. The company provides VSV-GP which is a proprietary oncolytic virus platform, which helps in destroying cancer cells and is u …
  • salesforce.com, inc.：企業のM&A・事業提携・投資動向
    salesforce.com, inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's salesforce.com, inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Bactiguard Holding AB (BACTI B)：医療機器：M&Aディール及び事業提携情報
    Summary Bactiguard Holding AB (Bactiguard) is a medical device manufacturer which develops and supplies infection protection solutions and antibiotics. The company’s product portfolio includes urinary catheters, foley catheters (BIP Foley catheters), endotracheal tubes and central venous catheters. …
  • TUV Nord AG：企業の戦略的SWOT分析
    TUV Nord AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Intermountain Healthcare Inc-医療機器分野：企業M&A・提携分析
    Summary Intermountain Healthcare Inc (Intermountain Healthcare) is a non-profit health care system. It provides health care services to Utah and Southeastern Idaho residents. It offers a wide range of clinical programs covering cardiovascular, intensive medicine, primary care, pediatric specialties, …
  • Eagle Materials Inc (EXP)：企業の財務・戦略的SWOT分析
    Eagle Materials Inc (EXP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Warpaint London plc (W7L)：企業の財務・戦略的SWOT分析
    Warpaint London plc (W7L) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Covis Pharma Sarl-製薬・医療分野：企業M&A・提携分析
    Summary Covis Pharma Sarl (Covis Pharma), a subsidiary of Concordia International Corp is a specialty pharmaceutical company that develops and markets drugs for the treatment of life-threatening conditions and chronic illnesses. The company develops products for central nervous system and rheumatic …
  • Hoosier Energy Rural Electric Cooperative, Inc.：発電所・企業SWOT分析
    Hoosier Energy Rural Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, …
  • Firstec Co., Ltd.
    Firstec Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Firstec Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆